Barclays analyst Peter Lawson lowered the firm’s price target on Adaptimmune (ADAP) to 46c from $1 and keeps an Underweight rating on the shares. The company’s Q1 product revenue was roughly in line with consensus but it evaluated strategic options ongoing to address its constrained capital position, the analyst tells investors in a research note.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ADAP:
- Adaptimmune Therapeutics Reports Q1 2025 Earnings
- ADAP Earnings Report this Week: Is It a Buy, Ahead of Earnings?
- Adaptimmune Therapeutics CFO Departure Terms Revised
- Adaptimmune downgraded to Hold from Buy at JonesResearch
- Adaptimmune Therapeutics: Hold Rating Amid Financial Uncertainties and Strategic Challenges